Allurion Technologies Inc. (ALUR)

NYSE: ALUR · Real-Time Price · USD
3.600
-0.300 (-7.69%)
At close: Feb 20, 2025, 4:00 PM
3.620
+0.020 (0.56%)
Pre-market: Feb 21, 2025, 9:25 AM EST
-7.69%
Market Cap 12.36M
Revenue (ttm) 34.75M
Net Income (ttm) -24.76M
Shares Out 3.43M
EPS (ttm) -11.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 482,182
Open 3.825
Previous Close 3.900
Day's Range 3.402 - 3.930
52-Week Range 2.367 - 98.750
Beta -0.73
Analysts Strong Buy
Price Target 50.00 (+1,288.89%)
Earnings Date Mar 20, 2025

About ALUR

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Employees 504
Stock Exchange NYSE
Ticker Symbol ALUR
Full Company Profile

Financial Performance

In 2023, Allurion Technologies's revenue was $53.47 million, a decrease of -16.73% compared to the previous year's $64.21 million. Losses were -$82.30 million, 102.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ALUR stock is "Strong Buy." The 12-month stock price forecast is $50.0, which is an increase of 1,288.89% from the latest price.

Price Target
$50.0
(1,288.89% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previous...

17 hours ago - Business Wire

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive sec...

2 days ago - Business Wire

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a cli...

3 days ago - Business Wire

Allurion Relaunches in France

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allu...

8 days ago - Business Wire

Allurion Technologies Shares Are Up Today: What's Going On?

Allurion Technologies ALUR shares are moving higher Friday, potentially in response to the company's Thursday announcement of a planned clinical study to evaluate the combination of its Allurion Progr...

27 days ago - Benzinga

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Shares of Allurion Technologies (ALUR) tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market.

27 days ago - Investopedia

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive sec...

27 days ago - Business Wire

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical stud...

4 weeks ago - Business Wire

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notificatio...

4 weeks ago - Business Wire

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription a...

5 weeks ago - Business Wire

Allurion Announces Positive Topline Results From AUDACITY Trial

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivo...

6 weeks ago - Business Wire

Allurion Technologies, Inc. Announces Reverse Stock Split

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determine...

2 months ago - Business Wire

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the List...

2 months ago - Business Wire

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to pa...

3 months ago - Business Wire

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executi...

3 months ago - Seeking Alpha

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quart...

3 months ago - Business Wire

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2...

3 months ago - Business Wire

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for...

4 months ago - Business Wire

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its pr...

4 months ago - Business Wire

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Re...

Other symbols: GEVOKULRLUCD
4 months ago - Benzinga

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical ...

4 months ago - Business Wire

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the...

5 months ago - Business Wire

Allurion Receives Continued Listing Standards Notice from NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Not...

6 months ago - Business Wire

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effect...

6 months ago - Business Wire

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Dire...

6 months ago - Business Wire